Ketorolac in Palatoplasty
Ketorolac in Palatoplasty: A Randomized Blinded Controlled Trial.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Matthew R Greives, MD,MS,FACS
- Phone Number: (713) 500-7275
- Email: Matthew.R.Greives@uth.tmc.edu
Study Contact Backup
- Name: Tien Do, DO
- Email: Tien.Do@uth.tmc.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas Health Science Center at Houston
-
Contact:
- Matthew R Greives, MD,MS,FACS
- Phone Number: 713-500-7275
- Email: Matthew.R.Greives@uth.tmc.edu
-
Contact:
- Tien Do, DO
- Email: Tien.Do@uth.tmc.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
-Patient with Cleft palate (Complete and incomplete), with or without cleft lip, unilateral or bilateral
Exclusion Criteria:
- Syndromic Cleft Palate patients
- Previous palatoplasty
- Major unrepaired cardiac malformation
- History of GI complications (GI Bleed, Gastric Ulceration)
- History of Renal disorder
- History of coagulopathy (As contraindication to NSAID use)
- Feeding tube dependency
- Patients whose parents refuse to consent to randomization
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Control Group
|
0.9% Normal Saline will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of normal saline.
|
|
Experimental: Experimental group (Ketorolac)
|
Ketorolac 0.5mg/kg will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of Ketorolac
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Volume of oral intake
Time Frame: from arrival to Post-Anesthesia Care Unit (PACU) to 24 hours post surgery
|
This will be measured in mL's of fluids
|
from arrival to Post-Anesthesia Care Unit (PACU) to 24 hours post surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain as assessed by the Faces, Legs, Activity, Cry, Consolability (FLACC) scale
Time Frame: immediately upon arrival at PACU
|
This scale has 5 questions and each is scored from 0-2,higher number indicating a worse outcome
|
immediately upon arrival at PACU
|
|
Pain as assessed by the Faces, Legs, Activity, Cry, Consolability (FLACC) scale
Time Frame: 24 hours post surgery
|
This scale has 5 questions and each is scored from 0-2,higher number indicating a worse outcome
|
24 hours post surgery
|
|
Pain as assessed by the Faces, Legs, Activity, Cry, Consolability (FLACC) scale
Time Frame: 48 hours post surgery
|
This scale has 5 questions and each is scored from 0-2,higher number indicating a worse outcome
|
48 hours post surgery
|
|
Pain as assessed by the Faces scale
Time Frame: 7 days post discharge
|
Subjective assessment of discomfort by parent, scored from 1-10, higher number indicating a worse outcome
|
7 days post discharge
|
|
Time to first oral intake
Time Frame: within 24 hours post surgery
|
within 24 hours post surgery
|
|
|
Number of participants with Post-operative bleeding that requires either transfusion or Unplanned return to Operating Room
Time Frame: 24 hours and 48 hours after surgery
|
24 hours and 48 hours after surgery
|
|
|
Amount of Post-operative narcotic usage (recorded in Morphine milligram Equivalents)
Time Frame: 7 days post surgery
|
7 days post surgery
|
|
|
Number of participants who need narcotic prescription at discharge
Time Frame: at discharge(24-48 hours post surgery)
|
at discharge(24-48 hours post surgery)
|
|
|
Renal function measured in mL/kg of urine output
Time Frame: from arrival to PACU to discharge (24-48 hours post surgery)
|
from arrival to PACU to discharge (24-48 hours post surgery)
|
|
|
Number of participants with post operative complications
Time Frame: 30 days post surgery
|
post operative complications include,Unplanned return to OR, ER or unplanned clinic visit , Infection, Fever
|
30 days post surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Matthew R Grieves, MD,MS,FACS, The University of Texas Health Science Center, Houston
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mouth Diseases
- Stomatognathic Diseases
- Stomatognathic System Abnormalities
- Congenital Abnormalities
- Lip Diseases
- Mouth Abnormalities
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Cleft Lip
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Indomethacin
- Indoles
- Ketorolac
Other Study ID Numbers
Other Study ID Numbers
- HSC-MS-21-0044
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.